| Mouaffaa Tello, | |
|
6500 Excelsior Blvd, St Louis Park, MN 55426-4702 | |
| (952) 993-5000 | |
| Not Available |
| Full Name | Mouaffaa Tello |
|---|---|
| Gender | Male |
| Speciality | Hospitalist |
| Experience | 11 Years |
| Location | 6500 Excelsior Blvd, St Louis Park, Minnesota |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1831622489 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 208M00000X | Hospitalist | 69169 (Minnesota) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Park Nicollet Methodist Hospital | Saint louis park, MN | Hospital |
| North Memorial Health | Robbinsdale, MN | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Park Nicollet Clinic | 7911819438 | 1529 |
News Archive
NPS Pharmaceuticals, Inc. (NASDAQ: NPSP), a global biopharmaceutical company pioneering and delivering therapies that transform the lives of patients with rare diseases worldwide, today announced that the company has initiated a global registration study of teduglutide in pediatric patients with Short Bowel Syndrome (SBS) who are dependent on parenteral support.
The University of Texas MD Anderson Cancer Center and Dragonfly Therapeutics, Inc., today announced a strategic collaboration to bring Dragonfly's TriNKET™ immunotherapy drug candidates to patients in clinical trials beginning in 2019.
4SC AG a drug discovery and development company focused on autoimmune and cancer indications, today announced the first treatment in a Phase I study evaluating 4SC-205, an oral Eg5 kinesin spindle protein inhibitor, in patients with solid tumours or malignant lymphomas.
An international team of researchers has identified three gene variants in the DNA of 486 people infected with HIV that appear to have helped some of the patients fight off the virus and delay the onset of full-blown AIDS.
"Although Congress this week approved an extension of unemployment insurance benefits, two health-related proposals initially linked to the measure - including extensions of COBRA subsidies for unemployed workers and enhanced federal Medicaid contributions for states — have stalled" (Villegas, 7/23).
› Verified 4 days ago
| Entity Name | Park Nicollet Clinic |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1780621904 PECOS PAC ID: 7911819438 Enrollment ID: O20031104000046 |
News Archive
NPS Pharmaceuticals, Inc. (NASDAQ: NPSP), a global biopharmaceutical company pioneering and delivering therapies that transform the lives of patients with rare diseases worldwide, today announced that the company has initiated a global registration study of teduglutide in pediatric patients with Short Bowel Syndrome (SBS) who are dependent on parenteral support.
The University of Texas MD Anderson Cancer Center and Dragonfly Therapeutics, Inc., today announced a strategic collaboration to bring Dragonfly's TriNKET™ immunotherapy drug candidates to patients in clinical trials beginning in 2019.
4SC AG a drug discovery and development company focused on autoimmune and cancer indications, today announced the first treatment in a Phase I study evaluating 4SC-205, an oral Eg5 kinesin spindle protein inhibitor, in patients with solid tumours or malignant lymphomas.
An international team of researchers has identified three gene variants in the DNA of 486 people infected with HIV that appear to have helped some of the patients fight off the virus and delay the onset of full-blown AIDS.
"Although Congress this week approved an extension of unemployment insurance benefits, two health-related proposals initially linked to the measure - including extensions of COBRA subsidies for unemployed workers and enhanced federal Medicaid contributions for states — have stalled" (Villegas, 7/23).
› Verified 4 days ago
| Entity Name | Group Health Plan Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1710924683 PECOS PAC ID: 1759293954 Enrollment ID: O20031105000417 |
News Archive
NPS Pharmaceuticals, Inc. (NASDAQ: NPSP), a global biopharmaceutical company pioneering and delivering therapies that transform the lives of patients with rare diseases worldwide, today announced that the company has initiated a global registration study of teduglutide in pediatric patients with Short Bowel Syndrome (SBS) who are dependent on parenteral support.
The University of Texas MD Anderson Cancer Center and Dragonfly Therapeutics, Inc., today announced a strategic collaboration to bring Dragonfly's TriNKET™ immunotherapy drug candidates to patients in clinical trials beginning in 2019.
4SC AG a drug discovery and development company focused on autoimmune and cancer indications, today announced the first treatment in a Phase I study evaluating 4SC-205, an oral Eg5 kinesin spindle protein inhibitor, in patients with solid tumours or malignant lymphomas.
An international team of researchers has identified three gene variants in the DNA of 486 people infected with HIV that appear to have helped some of the patients fight off the virus and delay the onset of full-blown AIDS.
"Although Congress this week approved an extension of unemployment insurance benefits, two health-related proposals initially linked to the measure - including extensions of COBRA subsidies for unemployed workers and enhanced federal Medicaid contributions for states — have stalled" (Villegas, 7/23).
› Verified 4 days ago
| Entity Name | Hutchinson Health |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1053508820 PECOS PAC ID: 0345330072 Enrollment ID: O20080312000695 |
News Archive
NPS Pharmaceuticals, Inc. (NASDAQ: NPSP), a global biopharmaceutical company pioneering and delivering therapies that transform the lives of patients with rare diseases worldwide, today announced that the company has initiated a global registration study of teduglutide in pediatric patients with Short Bowel Syndrome (SBS) who are dependent on parenteral support.
The University of Texas MD Anderson Cancer Center and Dragonfly Therapeutics, Inc., today announced a strategic collaboration to bring Dragonfly's TriNKET™ immunotherapy drug candidates to patients in clinical trials beginning in 2019.
4SC AG a drug discovery and development company focused on autoimmune and cancer indications, today announced the first treatment in a Phase I study evaluating 4SC-205, an oral Eg5 kinesin spindle protein inhibitor, in patients with solid tumours or malignant lymphomas.
An international team of researchers has identified three gene variants in the DNA of 486 people infected with HIV that appear to have helped some of the patients fight off the virus and delay the onset of full-blown AIDS.
"Although Congress this week approved an extension of unemployment insurance benefits, two health-related proposals initially linked to the measure - including extensions of COBRA subsidies for unemployed workers and enhanced federal Medicaid contributions for states — have stalled" (Villegas, 7/23).
› Verified 4 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Mouaffaa Tello, 6500 Excelsior Blvd, St Louis Park, MN 55426-4702 Ph: (952) 993-5000 | Mouaffaa Tello, 6500 Excelsior Blvd, St Louis Park, MN 55426-4702 Ph: (952) 993-5000 |
News Archive
NPS Pharmaceuticals, Inc. (NASDAQ: NPSP), a global biopharmaceutical company pioneering and delivering therapies that transform the lives of patients with rare diseases worldwide, today announced that the company has initiated a global registration study of teduglutide in pediatric patients with Short Bowel Syndrome (SBS) who are dependent on parenteral support.
The University of Texas MD Anderson Cancer Center and Dragonfly Therapeutics, Inc., today announced a strategic collaboration to bring Dragonfly's TriNKET™ immunotherapy drug candidates to patients in clinical trials beginning in 2019.
4SC AG a drug discovery and development company focused on autoimmune and cancer indications, today announced the first treatment in a Phase I study evaluating 4SC-205, an oral Eg5 kinesin spindle protein inhibitor, in patients with solid tumours or malignant lymphomas.
An international team of researchers has identified three gene variants in the DNA of 486 people infected with HIV that appear to have helped some of the patients fight off the virus and delay the onset of full-blown AIDS.
"Although Congress this week approved an extension of unemployment insurance benefits, two health-related proposals initially linked to the measure - including extensions of COBRA subsidies for unemployed workers and enhanced federal Medicaid contributions for states — have stalled" (Villegas, 7/23).
› Verified 4 days ago
Junqing Xin, MD Hospitalist Medicare: Accepting Medicare Assignments Practice Location: 6500 Excelsior Blvd, Methodist Hospitalist Program Suite 2-260, St Louis Park, MN 55426 Phone: 952-993-5000 | |
Kayleigh Dittes, MD Hospitalist Medicare: Medicare Enrolled Practice Location: 6500 Excelsior Blvd, St Louis Park, MN 55426 Phone: 952-993-5000 | |
Dr. Sara Ann Hoff, MD Hospitalist Medicare: Medicare Enrolled Practice Location: 6500 Excelsior Blvd, St Louis Park, MN 55426 Phone: 952-993-5000 |